Document is current

Article History

Received: 20 November 2024

Accepted: 4 February 2025

First Online: 28 February 2025

Declarations

:

: The study was approved by the Duke University Institutional Review Board (Pro00046131) and at every enrolling center (listed in the Acknowledgments). The protocol was approved by the relevant Institutional Review Boards and/or local Independent Ethics Committees prior to patient enrolment at every site. All patients provided written consent prior to entering the registry.

: Not applicable.

: ACS, JMW, JLT, SMP and MLN are employed by the Duke Clinical Research Institute, which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc to coordinate the IPF-PRO/ILD-PRO Registry. ACS also reports consulting fees from United Therapeutics. JLT also reports grants from AstraZeneca and CareDx and has participated on advisory boards for Altavant, Avalyn, Natera, Sanofi, Theravance. SMP reports research funding paid to the Duke Clinical Research Institute from Bristol Myers Squibb and Genentech and has participated on advisory boards for Altavant and Bristol Myers Squibb. TPW is a site investigator for the IPF-PRO/ILD-PRO Registry. GHJK reports grants from Boehringer Ingelheim and Genentech; consulting fees from Voiant Clinical (formerly MedQIA); and holds patent UC-2015-0324982-A1. TBL was an employee of Boehringer Ingelheim Pharmaceuticals, Inc at the time that these analyses were performed. JG is the founder of MedQIA, now Voiant Clinical, which received funding support from Boehringer Ingelheim Pharmaceuticals, Inc, to analyze HRCT scans for this project; he also reports grants from Boehringer Ingelheim. The University of California Los Angeles has a patent for the machine learning algorithm used in this project.